Cytokinetics, Incorporated

NasdaqGS:CYTK Stock Report

Market Cap: US$7.5b

Cytokinetics Management

Management criteria checks 2/4

Cytokinetics' CEO is Robert Blum, appointed in Feb 2006, has a tenure of 19.92 years. total yearly compensation is $14.37M, comprised of 5.7% salary and 94.3% bonuses, including company stock and options. directly owns 0.19% of the company’s shares, worth $14.46M. The average tenure of the management team and the board of directors is 4.3 years and 12.9 years respectively.

Key information

Robert Blum

Chief executive officer

US$14.4m

Total compensation

CEO salary percentage5.75%
CEO tenure19.9yrs
CEO ownership0.2%
Management average tenure4.3yrs
Board average tenure12.9yrs

Recent management updates

Recent updates

Cytokinetics: Small Label Differences With Big Commercial Stakes

Dec 22
User avatar

Precision Medicine And Late-stage Trials Will Expand Global Reach

Successful late-stage clinical trials, commercial readiness, and diversification in products position the company for strong growth and reduced dependence on a single therapy.

The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts

May 20
The Cytokinetics, Incorporated (NASDAQ:CYTK) Analysts Have Been Trimming Their Sales Forecasts

Cytokinetics Nears Approval: 'Buy' The New Potential Cardiology Franchise With Aficamten

Mar 16

These Analysts Think Cytokinetics, Incorporated's (NASDAQ:CYTK) Sales Are Under Threat

Mar 05
These Analysts Think Cytokinetics, Incorporated's (NASDAQ:CYTK) Sales Are Under Threat

Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates

Mar 02
Cytokinetics, Incorporated (NASDAQ:CYTK) Just Reported And Analysts Have Been Cutting Their Estimates

Cytokinetics Aligns For U.S. Launch Amid HCM Market Evolution

Dec 31

Cytokinetics: On The Cusp Of Commercialization

Nov 14

Cytokinetics: Aficamten Rolling NDA Submission Leads To Expansion Opportunities

Aug 13

Cytokinetics' Aficamten: Heartfelt Potential Amid Market Woes

Jul 24

Cytokinetics Decides To Go It Alone

May 24

CEO Compensation Analysis

How has Robert Blum's remuneration changed compared to Cytokinetics's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2025n/an/a

-US$752m

Jun 30 2025n/an/a

-US$606m

Mar 31 2025n/an/a

-US$615m

Dec 31 2024US$14mUS$826k

-US$590m

Sep 30 2024n/an/a

-US$576m

Jun 30 2024n/an/a

-US$545m

Mar 31 2024n/an/a

-US$531m

Dec 31 2023US$9mUS$790k

-US$526m

Sep 30 2023n/an/a

-US$527m

Jun 30 2023n/an/a

-US$540m

Mar 31 2023n/an/a

-US$431m

Dec 31 2022US$9mUS$742k

-US$389m

Sep 30 2022n/an/a

-US$282m

Jun 30 2022n/an/a

-US$216m

Mar 31 2022n/an/a

-US$258m

Dec 31 2021US$6mUS$709k

-US$215m

Sep 30 2021n/an/a

-US$229m

Jun 30 2021n/an/a

-US$156m

Mar 31 2021n/an/a

-US$135m

Dec 31 2020US$5mUS$682k

-US$127m

Sep 30 2020n/an/a

-US$114m

Jun 30 2020n/an/a

-US$140m

Mar 31 2020n/an/a

-US$132m

Dec 31 2019US$3mUS$656k

-US$122m

Compensation vs Market: Robert's total compensation ($USD14.37M) is above average for companies of similar size in the US market ($USD8.22M).

Compensation vs Earnings: Robert's compensation has increased whilst the company is unprofitable.

CEO

Robert Blum (61 yo)

19.9yrs
Tenure
US$14,368,345
Compensation

Mr. Robert I. Blum has been Chief Executive Officer, President and Director of Cytokinetics, Incorporated since January 22, 2007 and served as its Principal Financial Officer until May 08, 2024. Mr. Blum p...

Leadership Team

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director19.9yrsUS$14.37m0.19%
$ 14.5m
Sung Lee
EVP & CFO1.7yrsUS$6.00m0.015%
$ 1.1m
Fady Malik
Executive Vice President of Research & Development13.6yrsUS$5.37m0.066%
$ 5.0m
Andrew Callos
Executive VP & Chief Commercial Officer4.8yrsUS$4.39m0.0013%
$ 98.1k
James Spudich
Co-Founder & Member of Scientific Advisory Board28.4yrsUS$21.94kno data
Jeff Lotz
Vice President of Sales & Operations4.3yrsno datano data
Holly Laughlin
VP of Accounting & Corporate Controllerless than a yearno datano data
Steven Cook
Senior Vice President of Global Supply Chain Operations & Technical Operationsno datano datano data
Jeffrey Hessekiel
Executive VPless than a yearno datano data
Kari Loeser
VP & Chief Compliance Officer4.2yrsno datano data
Scott Jordan
Senior Vice President of Global Marketing & Commercial Strategy4.7yrsno datano data
Isaac Ciechanover
EVP of Corporate Development & Chief Business Officer1.6yrsno datano data
4.3yrs
Average Tenure
58.5yo
Average Age

Experienced Management: CYTK's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Robert Blum
CEO, President & Director19yrsUS$14.37m0.19%
$ 14.5m
James Spudich
Co-Founder & Member of Scientific Advisory Boardno dataUS$21.94kno data
B. Parshall
Independent Director12.9yrsUS$548.97k0.013%
$ 963.1k
James Sabry
Co-Founder & Chairman of Scientific Advisory Board17.8yrsUS$41.50kno data
Nancy Wysenski
Independent Director5.2yrsUS$538.14k0.019%
$ 1.5m
John Henderson
Independent Chairman16.9yrsUS$576.05k0.055%
$ 4.2m
John Lowe
Member of Scientific Advisory Boardno datano datano data
Thomas Pollard
Member of Scientific Advisory Boardno datano datano data
David Morgans
Member of Scientific Advisory Board9.5yrsUS$942.23kno data
Lawrence S. Goldstein
Member of Scientific Advisory Boardno datano datano data
John Solaro
Member of Scientific Advisory Boardno datano datano data
Muna Bhanji
Independent Director4.9yrsUS$524.80k0.013%
$ 998.5k
12.9yrs
Average Tenure
69yo
Average Age

Experienced Board: CYTK's board of directors are seasoned and experienced ( 12.9 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/01/05 07:54
End of Day Share Price 2026/01/02 00:00
Earnings2025/09/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Cytokinetics, Incorporated is covered by 35 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Carter GouldBarclays
Huidong WangBarclays
Jason ZemanskyBofA Global Research